Umezawa, K., Yoshida, M., Kamiya, M., Yamasoba, T
The promising PK data from the Phase 1 study suggests that nimacimab can be dosed once-a-month subcutaneously, which we believe would be a significant competitive advantage over once-a-week subcutaneous dosing of the current peptidic GLP-1 receptor agonists or even orally dosed GLP-1 receptor agonists due to their less desirable tolerability profile.
Why Soulera Wellness Why Soulera Wellness Physician-guided protocols built around your biology, your goals, and your long-term performance
Phase 3 Development Program Meanwhile, Following the positive Phase 2 findings, Lilly advanced eloralintide into Phase 3 development
Persistently elevated cortisol can blunt GLP-1 signalling and make blood sugar harder to manage
It helps regulate blood sugar, slows stomach emptying, and promotes a feeling of fullness, which leads to reduced appetite and calorie intake